932699-03-1
Chemical Structure
A20FMDV2
- CAS No.: 932699-03-1
- Formula:C93H163N31O28
- Molecular Weight:2163.48
SMILES: O=C(N[C@@H](C)C(N[C@@H](C(C)C)C(N1[C@@H](CCC1)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@H](O)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC(N)=O)N
Biological Activity: A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC50 values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
A20FMDV2 | 99.80% | A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC50 values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Slack RJ, et al. Pharmacological Characterization of the αvβ6 Integrin Binding and Internalization Kinetics of the Foot-and-Mouth Disease Virus Derived Peptide A20FMDV2. Pharmacology. 2016;97(3-4):114-125. [Content Brief]
- [2]. Hausner SH, et al. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. Cancer Res. 2007 Aug 15;67(16):7833-40. [Content Brief]
Keywords
